Patent Application
20210196899
The present invention relates to a drug-coated microneedle and a method of manufacturing the same, and more particularly to a drug-coated microneedle that delivers a drug by physically piercing the stratum corneum of the skin and a method of manufacturing the same.
The skin, which protects the human body from the external environment and is the most important biochemical and physical tissue, is broadly divided into the epidermis, dermis and hypodermis. The stratum corneum, which is the outermost layer of the skin, has a function of regulating moisture evaporation and absorption by the skin and a barrier function against penetration of chemicals, toxic substances, bacteria and the like. As for the stratum corneum, keratinocytes produced in the basal layer take about 14 days to reach the granular layer. In the granular layer, when keratinization is initiated by the action of keratohyalin, the body fluid in the cells escapes and the cells are keratinized in a flattened state. Millions of keratinocytes are released from the skin every day, and new keratinocytes are produced to replace the same.
One of the signs of skin aging is that the skin loses vitality and elasticity with an increase in the cell regeneration cycle due to decreased ability to shed dead cells. Therefore, many attempts are being made to remove the epidermal layer through a skin-peeling technique to thus stimulate cell regeneration in the basal layer in order to restore skin elasticity.
Cosmetics for exfoliation developed to date may be roughly classified into three types of exfoliation methods. The first is a method of finely cutting the epidermis by physical action such as skin friction or a laser, the second is a chemical method that uses chemical components such as AHA (alpha-hydroxy acid), BHA (beta-hydroxy acid), urea and the like, which have a keratolysis effect, and the third is a method of removing keratin using proteolytic enzymes having a function of exfoliation. In these peeling methods, the skin is first peeled off, and then the regenerative capacity of the skin itself is induced.
However, in the case of physical abrasion, the skin swells red due to significant irritation when applied to the skin, or intense pain occurs, so an anesthetic is used during the procedure, and thus there is a problem in that it is difficult to use at home. Also, in the case of chemical peeling, it is difficult to use at home, and there is a problem in that pigmentation-related abnormal skin discoloration, infection or complications such as permanent sequelae such as scars may occur. Moreover, peeling using proteolytic enzymes is expensive, and is also unsuitable for use at home due to problems related to the storage and use thereof.
With the goal of solving the above problems, research is ongoing into the application of sponge spicules to cosmetic compositions. Korean Patent No. 0937389 discloses a method of preparing a skin care cosmetic composition including extracting microneedles from sponges using a hydrogen peroxide solution, increasing the porosity of the extracted microneedles, coating the microneedles having the increased porosity with a mixed solution of a stem-cell-derived material and a skin active ingredient through immersion, and freeze-drying the mixed solution in which the microneedles are immersed, and Korean Patent No. 1810231 discloses a cosmetic composition for reducing acne and atopy, containing, as active ingredients, a complex extract composed of a propolis extract, a royal jelly extract, a golden extract and a red ginseng extract, and a microneedle powder. Korean Patent No. 1854446 discloses a cosmetic composition containing a Sageretia theezans extract and a microneedle.
However, when the microneedle is immersion-coated or simply coated with the active ingredient drug, the immersion-coating rate may be low depending on the type of drug, or the drug may not be released after penetration into the skin, so the effects thereof are insignificant.
Therefore, the present inventors have endeavored to solve the problems encountered in the related art, and thus ascertained that, when using a microneedle having a drug attached thereto through disulfide bonding, the drug may be released through a redox reaction after penetration into the skin, making it possible to effectively deliver even a drug having excellent functionality but low skin permeability, thus culminating in the present invention.
An objective of the present invention is to provide a microneedle having excellent drug delivery capability and a method of manufacturing the same.
Another objective of the present invention is to provide a cosmetic composition, which has excellent drug delivery capability and is easy to use, and is thus usable at home.
In order to accomplish the above objectives, the present invention provides a method of manufacturing a drug-coated microneedle, which is represented by Chemical Formula 1 and in which a drug is released through a redox reaction after penetration into the skin, including: (a) manufacturing a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group by modifying the surface of a silica-(SiO2)-containing microneedle; (b) manufacturing a drug having a sulfhydryl (—SH) functional group by binding a drug with a linker having a sulfhydryl (—SH) functional group; and (c) subjecting the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction.
In the present invention, the modifying the surface of the silica-(SiO2)-containing microneedle may be performed by subjecting the silica-(SiO2)-containing microneedle to stirring with any one selected from the group consisting of (3-mercaptopropyl)methyldimethoxysilane, (3-mercaptopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]ethylenediamine, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and 3,3′ -dithiodipropionic acid.
In the present invention, the oxidation reaction of the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group may be performed using at least one oxidant selected from the group consisting of iodine, potassium phosphate, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), dehydroascorbic acid, hydrogen peroxide (H2O2), and oxygen (O2).
In addition, the present invention provides a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into the skin.
[Chemical Formula 1]
MN-S—S-D
In Chemical Formula 1, MN is a silica-(SiO2)-containing microneedle, S—S is a disulfide bond, and D is a drug.
In the present invention, the silica-(SiO2)-containing microneedle may be an acicular spicule derived from a sponge.
In the present invention, the microneedle represented by Chemical Formula 1 may be manufactured by attaching a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group and a drug having a sulfhydryl (—SH) functional group to each other.
In the present invention, the silica-(SiO2)-containing microneedle may include the sulfhydryl (—SH) functional group in an amount of 0.8×10−6 mol/g to 10×10−6 mol/g.
In the present invention, the drug having the sulfhydryl (—SH) functional group may be at least one selected from the group consisting of Chemical Formulas 2 to 8 below.
[Chemical Formula 2]: Lys-His-Gly-X
[Chemical Formula 3]: Gly-His-Lys-X
[Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X
[Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X
[Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X
[Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X
In Chemical Formulas 2 to 8, X is at least one selected from the group consisting of thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and cysteine.
In addition, the present invention provides a cosmetic composition including the above microneedle.
In the present invention, the cosmetic may be selected from the group consisting of a softening lotion, nourishing lotion, nourishing cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, and powder.
According to the present invention, a drug-coated microneedle is capable of effectively delivering a drug having excellent functionality but low skin permeability, and is thus useful as a material for functional cosmetics for whitening, wrinkle reduction, inflammation reduction and the like.
When a drug having excellent functionality but low skin permeability is attached to a microneedle through disulfide bonding, the drug penetrates into the stratum corneum of the skin along with the microneedle and is then released through a redox reaction, so the present invention is intended to confirm that the drug can be effectively delivered.
In the present invention, a drug-coated microneedle is manufactured by modifying the surface of a microneedle derived from an animal sponge to afford a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group, binding a drug with a linker having a sulfhydryl (—SH) functional group to afford a drug having a sulfhydryl (—SH) functional group, and performing an oxidation reaction therebetween. Based on the results of evaluation of cytotoxicity and collagen production capability of the drug-coated microneedle thus manufactured, it is confirmed that the drug-coated microneedle has no cytotoxicity but has superior collagen production effects.
Therefore, an aspect of the present invention pertains to a method of manufacturing a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into the skin, including: (a) manufacturing a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group by modifying the surface of a silica-(SiO2)-containing microneedle; (b) manufacturing a drug having a sulfhydryl (—SH) functional group by binding a drug with a linker having a sulfhydryl (—SH) functional group; and (c) subjecting the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction.
[Chemical Formula 1]
MN-S—S-D
In Chemical Formula 1, MN is a silica-(SiO2)-containing microneedle, S—S is a disulfide bond, and D is a drug.
In the present invention, the silica-(SiO2)-containing microneedle may be an acicular spicule derived from a sponge. Examples of the sponge may include, but are not limited to, Spongilla lacustris, Spongilla fragilis, Ephydatia fluviatilis, and the like.
The size of the acicular spicule is not particularly limited, and an acicular spicule having a length of about 100 to 300 μm and a width of about 10 to 30 μm may be used.
The silica-(SiO2)-containing microneedle that is used is preferably one purified in a manner in which an acicular spicule powder derived from a sponge is sequentially added with sulfuric acid and sodium hydroxide, stirred, filtered, and washed.
In order to penetrate into the skin, the drug, such as a peptide, which alone has difficulty penetrating into the skin, has to be attached to the microneedle. In order to attach the drug to the microneedle through disulfide bonding, a sulfhydryl (—SH) functional group has to be introduced to each of the drug and the microneedle.
First, in the present invention, a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group is manufactured by modifying the surface of a silica-(SiO2)-containing microneedle.
Here, the modifying the surface of the silica-(SiO2)-containing microneedle is performed by subjecting the silica-(SiO2)-containing microneedle to stirring with any one selected from the group consisting of (3-mercaptopropyl)methyldimethoxysilane, (3-mercaptopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]ethylenediamine, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and 3,3′-dithiodipropionic acid.
Although varying depending on the shape of the microneedle, the type of mercaptosilane for surface modification, and the reaction conditions, the silica-(SiO2)-containing microneedle thus manufactured may include the sulfhydryl (—SH) functional group in an amount of 0.8×10−6 mol/g to 10×10−6 mol/g, and preferably in an amount exceeding 2.0×10−6 mol/g, taking into consideration the surface area of the microneedle.
In the present invention, a drug having a sulfhydryl (—SH) functional group is manufactured by binding a drug with a linker having a sulfhydryl (—SH) functional group.
As the drug, any material may be used without particular limitation, so long as it penetrates into the skin and is capable of increasing skin improvement effects, such as skin-soothing effects, vitality enhancement effects, antioxidant effects, whitening effects, moisturizing effects, skin regeneration effects, anti-aging effects, anti-inflammatory effects, collagen synthesis promotion effects, and the like. Not only a synthetic compound but also a peptide may be used.
Examples of the linker having the sulfhydryl (—SH) functional group may include, but are not limited to, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, cysteine, and the like.
When the drug is a peptide, the use of cysteine as the linker may cause the properties thereof to vary depending on the amino acid sequence and structure, and thus the use of thioglycolic acid, 3-mercaptopropionic acid or 11-mercaptoundecanoic acid is preferable, with the use of thioglycolic acid, having a low molecular weight, being most preferable.
In the present invention, examples of the drug having the sulfhydryl (—SH) functional group manufactured by binding the peptide or compound drug with the linker having the sulfhydryl (—SH) functional group may include, but are not limited to, Chemical Formulas 2 to 8 below.
[Chemical Formula 2]: Lys-His-Gly-X
[Chemical Formula 3]: Gly-His-Lys-X
[Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X
[Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X
[Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X
[Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X
In Chemical Formulas 2 to 8, X is at least one selected from the group consisting of thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and cysteine.
In the present invention, a drug-coated microneedle is manufactured by subjecting the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction.
As the oxidant for the oxidation reaction, any material may be used without particular limitation, so long as it is able to attach the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to each other through oxidation. Examples of the oxidant may include iodine, potassium phosphate, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), dehydroascorbic acid, hydrogen peroxide (H2O2), oxygen (O2), and the like.
In the present invention, a drug-coated microneedle capable of releasing a drug through a redox reaction after penetration into the skin is manufactured using the above method.
Therefore, another aspect of the present invention pertains to a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into the skin.
[Chemical Formula 1]
MN-S—S-D
In Chemical Formula 1, MN is a silica-(SiO2)-containing microneedle, S—S is a disulfide bond, and D is a drug.
In addition, the present invention pertains to a cosmetic composition including the drug-coated microneedle.
The amount of the drug-coated microneedle may vary depending on the type of cosmetic, and may be 0.1 to 10.0 wt % based on the total weight of the cosmetic composition.
Examples of the cosmetics may include, but are not limited to, a softening lotion, nourishing lotion, nourishing cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, and the like.
In the cosmetic composition, other ingredients may be appropriately combined within a range that does not impair the purpose according to the present invention depending on the type or purpose of use of the formulation, in addition to the drug-coated microneedle.
Moreover, depending on the quality or function of the final product, the cosmetic composition may further include materials typically used in the art, such as fatty materials, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspension agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal-ion-sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activating agents, and adjuvants commonly used in the cosmetic or dermatological field, such as any other ingredients commonly used in cosmetic compositions.
Here, it is preferable that the adjuvants and the mixing ratio thereof be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.
A better understanding of the present invention will be given through the following examples. These examples are merely set forth to illustrate the present invention, and are not to be construed as limiting the scope of the present invention, as will be apparent to those skilled in the art.
1-1: Purification of Silica-(SiO2)-Containing Microneedle
An acicular spicule (289 g) derived from Spongilla fragilis Leidy and sulfuric acid (80 g) were placed in a reactor, stirred for 1 hr, added with water, further stirred, and filtered. The acicular spicule was washed with water, further stirred for 1 to 2 hr, added with NaOH and HNO3, stirred, adjusted to a pH of 6 to 8, and washed with water. Finally, the acicular spicule was washed with ethanol, filtered, and dried.
1-2: Surface Modification of Silica-(SiO2)-Containing Microneedle
In order to introduce a sulfhydryl (—SH) functional group to the purified acicular spicule (silica-(SiO2)-containing microneedle), hydrolysis and dealkoxylation were performed.
1-2-1: Surface Modification Using Hydrolysis
As shown in [Scheme 1] below, 10 g of the purified microneedle, 0.1 to 3.0 ml of (3-mercaptopropyl)trimethoxysilane (MPTMS), and 100 g of a mixed water/ethanol solution (50% ethanol) were placed in a reactor and then allowed to react at room temperature for 4 hr. The resulting reaction product was washed and then dried under reduced pressure at 70° C. for 4 hr, thus obtaining a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group (No. 1).
1-2-2 to 1-2-4: Surface Modification Using Hydrolysis
The reaction was carried out under the conditions of Example 1-2-1, with the exception that the reaction time was changed to 8, 16 and 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 2 to 4).
1-2-5 and 1-2-6: Surface Modification Using Hydrolysis
The reaction was carried out under the conditions of Example 1-2-1, with the exception that the reaction temperature was adjusted to 40° C. and 60° C. and the reaction time was changed to 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 5 and 6).
The molar number of the sulfhydryl (—SH) functional group per g of the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group obtained as described above was measured using a spectrophotometer (Agilent 8453 UV Spectrophotometer) through an Ellman assay. The results thereof are shown in Table 1 below and in
As is apparent from Table 1 and
1-2-7: Surface Modification using Dealkoxylation
As shown in [Scheme 2] below, 5.02 g of the purified microneedle, 0.1 to 3.0 ml of (3-mercaptopropyl)trimethoxysilane (MPTMS), and 50 g of toluene were placed in a reactor and then allowed to react at 90° C. for 4 hr. The resulting reaction product was washed and then dried under reduced pressure at 70° C. for 20 hr, thus obtaining a silica-(SiO2)-containing microneedle having a sulfhydryl (—SH) functional group (No. 1).
1-2-8 to 1-2-10: Surface Modification Using Dealkoxylation
The reaction was carried out under the conditions of Example 1-2-7, with the exception that the reaction time was changed to 8, 16 and 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 2 to 4).
1-2-11 and 1-2-12: Surface Modification Using Dealkoxylation
The reflux reaction was carried out under the conditions of Example 1-2-7, with the exception that the reaction time was changed to 16 and 24 hr at a pH of 2 to 3. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 5 and 6).
The molar number of the sulfhydryl (—SH) functional group per g of the silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group obtained as described above was measured using a spectrophotometer (Agilent 8453 UV Spectrophotometer) through an Ellman assay. The results thereof are shown in Table 2 below and in
As is apparent from Table 2 and
1-3: Binding of Drug with Linker having Sulfhydryl (—SH) Functional Group
1-3-1: Binding of Peptide Drug with Linker
The names and abbreviations of the amino acids used in the present invention are set forth below.
Lys: lysine/His: histidine/Gly: glycine/Ser: serine/Thr: threonine/Arg: arginine/Gln: glutamine/Met: methionine/Glu: glutamic Acid
1-3-1-1: Preparation of Sulfhydryl-Tripeptides Represented by Chemical Formula 2 and Chemical Formula 3
As shown in methods (1) to (6) below and in [Scheme 3] below, the peptides were continuously coupled according to the same synthesis cycle. Specifically, the following amino acids in the order of amino acid sequences of compounds 2 and 3 were placed in a reaction vessel and peptide bonding progressed, and finally, a linker X having a sulfhydryl (—SH) functional group [thioglycolic acid (TA), 3-mercaptopropionic acid (MPA), 11-mercaptoundecanoic acid (MUD) and cysteine (CS)] was added thereto and amide bonding progressed, thus preparing sulfhydryl-tripeptides represented by Chemical Formula 2 and Chemical Formula 3.
(1) Washing three times with DMF solvent (10 mL)/washing three times with dichloromethane (DCM) solvent (10 mL)
(2) Deprotection two times for 10 min using 20% (w/v) piperidine DMF solution (3 mL)
(3) Washing five times with DMF solvent (10 mL)
(4) Fmoc-amino acid addition
(5) Amino acid activation and coupling for 2 hr by adding coupling reagent
(6) Washing five times with DMF solvent (10 mL)
[Chemical Formula 2]: Lys-His-Gly-X
[Chemical Formula 3]: Gly-His-Lys-X
1-3-1-2: Preparation of Sulfhydryl-Pentapeptides Represented by Chemical Formula 4 and Chemical Formula 5
Sulfhydryl-pentapeptides represented by Chemical Formula 4 and Chemical Formula 5 were prepared through the peptide synthesis method described in 1-3-1-1 above and as shown in [Scheme 4] below.
[Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X
[Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X
1-3-1-3: Preparation of Sulfhydryl-Hexapeptides Represented by Chemical Formula 6 and Chemical Formula 7
Sulfhydryl-hexapeptides represented by Chemical Formula 6 and Chemical Formula 7 were prepared through the peptide synthesis method described in 1-3-1-1 above and as shown in [Scheme 5] below.
[Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X
[Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X
1-3-2: Binding of Synthetic Compound Drug with Linker
As shown in [Scheme 6] below, dehydroascorbic acid was reacted with a lipase and a linker X having a sulfhydryl (—SH) functional group [thioglycolic acid (TA), 3-mercaptopropionic acid (MPA), 11-mercaptoundecanoic acid (MUD) and cysteine] and reduced, thus preparing a synthetic compound having a sulfhydryl (—SH) functional group, as represented by Chemical Formula 8 below.
1-4: Manufacture of Microneedle having Drug Attached thereto through Disulfide Bonding
The silica-(SiO2)-containing microneedle having the sulfhydryl (—SH) functional group manufactured in Example 1-2 and the drug having the sulfhydryl (—SH) functional group manufactured in Example 1-3 were subjected to an oxidation reaction and thus attached to each other through disulfide bonding.
1-4-1: Attachment of Peptide Drug
1-4-1-1: Disulfide Bonding through Oxidation using Iodine
0.3 g of the sulfhydryl microneedle manufactured in Example 1-2 and 5.0 mL of purified water/ethanol (50% ethanol) were placed in a reaction vessel and stirred for 60 min so that the microneedle was uniformly dispersed, after which 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.) was added thereto, 1.2 μmol of the peptide of each of Chemical Formulas 2 to 7 prepared in Example 1-3-1 was added thereto, and the resulting mixture was stirred. After termination of the reaction, washing five times or more with 5.0 mL of ethanol and drying under reduced pressure at 25° C. for 12 hr were performed, thus manufacturing a microneedle having a peptide attached thereto through disulfide bonding.
1-4-1-2: Disulfide Bonding through Oxidation using Potassium Phosphate
A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of purified water was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 40.8 μg (0.3 μmol) of potassium phosphate (KH2PO4, molar molecular weight: 136.06 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-1-3: Disulfide Bonding through Oxidation using DDQ
A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of dichloromethane was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 68.1 μg (0.3 μmol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ, molar molecular weight: 227.0 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-1-4: Disulfide Bonding through Oxidation Using Dehydroascorbic Acid
A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of a 0.2 M sodium acetate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 52.84 μg (0.3 μmol) of dehydroascorbic acid (molar molecular weight: 174.11 g/mol) was used in lieu of 12.7 μg (0.5 mol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-1-5: Disulfide Bonding through Oxidation Using Hydrogen Peroxide
A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of a 0.2 M sodium phosphate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 10 μL of 30% hydrogen peroxide was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-2: Attachment of Synthetic Compound Drug
1-4-2-1: Disulfide Bonding through Oxidation Using Iodine
0.3 g of the sulfhydryl microneedle manufactured in Example 1-2 and 5.0 mL of purified water/ethanol (50% ethanol) were placed in a reaction vessel and stirred for 60 min so that the microneedle was uniformly dispersed, after which 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.) was added thereto, 112.6 μg (0.45 μmol) of the compound of Chemical Formula 8 prepared in Example 1-3-2 was added thereto, and the resulting mixture was stirred. After termination of the reaction, washing five times or more with 5.0 mL of purified water and ethanol and drying under reduced pressure at 70° C. for 12 hr were performed, thus manufacturing a microneedle having ascorbic acid attached thereto through disulfide bonding.
1-4-2-2: Disulfide Bonding through Oxidation Using Potassium Phosphate
A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of purified water was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 40.8 μg (0.3 μmol) of potassium phosphate (KH2PO4, molar molecular weight: 136.06 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-2-3: Disulfide Bonding through Oxidation Using DDQ
A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of dichloromethane was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 68.1 μg (0.3 μmol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ, molar molecular weight: 227.0 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-2-4: Disulfide Bonding through Oxidation Using Dehydroascorbic Acid
A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of a 0.2 M sodium acetate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 52.84 μg (0.3 μmol) of dehydroascorbic acid (molar molecular weight: 174.11 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
1-4-2-5: Disulfide Bonding through Oxidation Using Hydrogen Peroxide
A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of a 0.2 M sodium phosphate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 10 μL of 30% hydrogen peroxide was used in lieu of 12.7 μg (0.5 μmol) of iodine (I2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).
Experimental Example 1: Evaluation of Collagen Synthesis Promotion Capability of Drug having Sulfhydryl (—SH) Functional Group
1-1: Cell Line Selection and Culture
Fibroblasts (CCD-986SK) purchased from the Korea Cell Line Bank were seeded to the bottom of a culture dish, after which DMEM (Dulbecco's Modified Eagle's Medium) containing penicillin (100 IU/mL), streptomycin (100 μg/mL) and 10% fetal bovine serum (FBS) was added thereto, followed by culture in a 5% CO2 incubator at 37° C.
1-2: Cytotoxicity Test Method (CCK Assay)
Fibroblasts (CCD-986SK) were aliquoted in an amount of 1.0×104 (to 5.0×104) cells per well into a 24-well (or 96-well) plate and then cultured for 24 hr under cell culture conditions. The culture medium was discarded, followed by washing with PBS and replacement with new DMEM not containing 10% FBS, after which the cells were treated with a test substance (GHK and GHK-TA) at a predetermined concentration and then cultured for 24 hr. Thereafter, CCK was added to the culture medium in an amount equivalent to 1/10 thereof, followed by measurement at 450 nm using an ELISA reader, and the results thereof are shown in
As shown in
1-3: Measurement of Collagen Content in Cell Line
Fibroblasts (CCD-986SK) were aliquoted in an amount of 1.0×104 to 5.0×104 cells per well into a 24-well (or 96-well) plate and then cultured for 24 hr under cell culture conditions. The culture medium was discarded, followed by washing with PBS, after which the cells were treated with a test substance (Tripeptide (GHK), (GHK)-TA prepared in Example 1-3-1-1, Pentapeptide (KTTKS), (KTTKS)-TA prepared in Example 1-3-1-2, Hexapeptide (EEMQRR), and (EEMQRR)-TA prepared in Example 1-3-1-3) and new DMEM was added thereto, followed by culture for 24 hr. The culture supernatant was collected and the amount of collagen was measured as described below according to the guidelines of the Ministry of Food and Drug Safety, and the results thereof are shown in
100 μl of an antibody-PoD conjugate solution was placed in each well, after which the culture solution and a standard solution were added in an amount of 20 μL thereto and cultured at 37° C. for 3 hr. The culture solution was removed from the well, followed by washing four times with 400 μL of a phosphate-buffered saline (PBS). 100 μL of a color development reagent (Procollagen type I peptide EIA kit, Takara Biomedical Co.) was added thereto, followed by culture at room temperature for 15 min, addition with 100 μL of 1 N sulfuric acid, and measurement at 450 nm using an ELISA reader.
As shown in
In the case of KTTKS, the collagen synthesis and promotion effects increased in proportion to the concentration up to 50 to 200 ppm, and the effects of sulfhydryl KTTKS (KTTKS-TA) were vastly superior compared to KTTKS.
In the case of EEMQRR, it was found that the use of thioglycolic acid (TA) as the linker exhibited superior collagen synthesis and promotion effects compared to the use of cysteine (CS) as the linker.
Experimental Example 2: Evaluation of Collagen Synthesis Promotion Capability of Drug-Coated Microneedle
2-1: Collagen Production Capability Depending on Linker X having Sulfhydryl (—SH) Functional Group
0.3 g of the drug-coated microneedle (GHK-TA-MN, GHK-MPA-MN, GHK-CS-MN) manufactured in Example 1-4 was added with 40 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 840 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in
As shown in
2-2: Collagen Production Capability Depending on Concentration of GSH (Glutathione)
0.3 g of the drug-coated microneedle (GHK-MPA-MN, GHK-CS-MN, KTTKS-TA-MN, GHK-TA-MN) manufactured in Example 1-4 was added with 40 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 840 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in
Also, 0.3 g of the drug-coated microneedle (GHK-MPA-MN, GHK-CS-MN, KTTKS-TA-MN, GHK-TA-MN) manufactured in Example 1-4 was added with 100 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 180 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in
As shown in
Preparation Example 1: Cosmetic Containing Drug-Coated Microneedle
1-1: Preparation of Ampoule
A cream was prepared with the composition of Table 3 below.
Spongilla tripeptide-1
Experimental Example 3: Efficacy of Cosmetic Containing Drug-Coated Microneedle
The ampoule prepared in Preparation Example 1 (material name: Spongilla tripeptide-1) was gently applied twice a day for 4 weeks (morning and evening) onto the skin in the direction of skin texture in an amount as large as a 100-won coin size, lightly tapped, and allowed to be absorbed into the skin. Skin changes were observed using a microscope on the 2nd week and the 4th week of sample application, and the results thereof are shown in
As shown in
Although specific embodiments of the present invention have been disclosed in detail above, it will be obvious to those skilled in the art that the description is merely of preferable exemplary embodiments and is not to be construed to limit the scope of the present invention. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
According to the present invention, a drug-coated microneedle is capable of effectively delivering a drug having excellent functionality but low skin permeability, and is thus useful as a material for functional cosmetics for whitening, wrinkle reduction, inflammation reduction and the like.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2018-0076060 | Jun 2018 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2018/016032 | 12/17/2018 | WO | 00 |
